hologic inc (HOLX) Details
Hologic, Inc. develops, manufactures, and supplies diagnostics, medical imaging systems, and surgical products for the healthcare needs of women. The company’s Breast Health segment offers full field digital mammography systems, breast tomosynthesis, C-View systems, Selenia full field digital mammography platform, healthcome mammography products, screen-film mammography systems, SecurView workstation, computer aided detection systems, stereotactic breast biopsy systems, breast biopsy products, breast brachytherapy products, MammoPad breast cushions, and photoconductor coatings, Sentinelle medical MRI breast coils and workstations, and Trident specimen radiography system. Its Diagnostics segment provides APTIMA family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assays, instrumentation, Invader chemistry platform, Cervista HPV tests, and ThinPrep system. The company’s GYN Surgical segment offers NovaSure system to treat women with excessive menstrual bleeding; MyoSure system for the hysteroscopic removal of fibroids; Towerfree Hysteroscopy System for the visualization and inspection of the uterine cavity; Aquilex Fluid Control System to measure the inflow and outflow of fluid from the patient during hysteroscopic procedures; and Adiana system, a procedure for permanent female contraception. Its Skeletal Health segment provides QDR X-Ray bone densitometers that assess the bone density of fracture sites; Sahara clinical bone sonometers, which assess the bone density of heels; and Mini C-Arm imaging systems to perform minimally invasive surgical procedures on a patient’s extremities. The company sells its products through direct sales and service forces, a network of independent distributors, and sales representatives primarily in the United States, Europe, and the Asia-Pacific. Hologic, Inc. was founded in 1985 and is headquartered in Bedford, Massachusetts.
Last Reported Date: 11/28/12
Founded in 1985
hologic inc (HOLX) Top Compensated Officers
Chief Executive Officer, President and Direct...
Total Annual Compensation: $899.7K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $574.8K
Senior Vice President and General Manager of ...
Total Annual Compensation: $434.8K
Chief Administrative Officer, Senior Vice Pre...
Total Annual Compensation: $405.5K
Senior Vice President and General Manager of ...
Total Annual Compensation: $379.0K
Compensation as of Fiscal Year 2012.
Hologic Receives FDA Approval for a New Low-dose 3D Mammography (Breast Tomosynthesis) Solution for Breast Cancer Screening
May 21 13
Hologic Inc. announced that the U.S. Food and Drug Administration (FDA) approved the use of Hologic's new C-View 2D imaging software. C-View 2D images may now be used in place of the conventional 2D exposure previously required as part of a Hologic 3D mammography (breast tomosynthesis) screening exam. Approval of C-View software is an important evolution in Hologic's 3D mammography screening program. Eliminating the need for additional 2D exposures will provide a better experience for patients.
Hologic Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 30, 2013; Provides Earnings Guidance for the Third Quarter Ending June 29, 2013; Revises Earnings Guidance for the Full Year Ending September 28, 2013
May 6 13
Hologic Inc. reported unaudited consolidated earnings results for the second quarter and six months ended March 30, 2013. For the quarter, the company reported total revenues of $612.66 million compared to total revenues of $471.17 million for the same period a year ago. Income from operations was $5.54 million compared to $10.13 million last year. Loss before income taxes was $73.75 million compared to $58.61 million last year. Net loss was $51.10 million, or $0.19 per basic and diluted share, compared with a net loss of $40.27 million, or $0.15 per basic and diluted share, in the second quarter of fiscal 2012. The increase in revenues compared to the same period in the prior year was driven by the inclusion of Gen-Probe revenues; An increase in service revenues from the company's increased installed base of digital mammography systems; and Higher sales of: tomosynthesis systems; breast biopsy products; and MyoSure hysteroscopic tissue removal (MyoSure) systems. Excluding the effect of an adjustment of negative $6.4 million related to purchase accounting, non--GAAP adjusted revenues were $619.1 million, an increase of 31.4% compared to revenues of $471.2 million in the second quarter of fiscal 2012. This adjustment related to contingent revenue earned and received under Gen--Probe's collaboration agreement with Novartis, for which the cash was collected by the company following the acquisition. If not for this purchase accounting adjustment, the company would have recognized revenues upon collection in the second quarter of fiscal 2013. The company's non--GAAP adjusted net income increased 8.1% to $93.8 million, or $0.35 per diluted share, in the second quarter of fiscal 2013 compared to $86.8 million, or $0.33 per diluted share, for the same period in the prior year. Adjusted EBITDA was $211.78 million compared to $157.40 million last year.
For the six months, the company reported total revenues of $1,244.03 million compared to total revenues of $943.88 million for the same period a year ago. Income from operations was $68.77 million compared to $76.89 million last year. Loss before income taxes was $81.10 million compared to $18.70 million last year. Net loss was $47.99 million, or $0.18 per basic and diluted share, compared with a net loss of $19.46 million, or $0.07 per basic and diluted share last year. Excluding the effect of a net adjustment of negative $19.7 million, primarily related to purchase accounting, non--GAAP adjusted revenues were $1.26 billion, an increase of 33.9% compared to revenues of $943.9 million for the six months ended March 24, 2012. The company's non-GAAP adjusted net income increased 10.6% to $195.6 million, or $0.72 per diluted share, for the six months ended March 30, 2013 compared to $176.9 million, or $0.67 per diluted share, for the same period in the prior year. Adjusted EBITDA was $439.28 million compared to $319.66 million last year.
For the third quarter ending June 29, 2013, the company expects revenues of $625 million to $630 million. Year--over--year, this represents an increase of 33% to 34% over third quarter fiscal 2012 revenues of $470.2 million. The increase is expected to be driven primarily by the Gen--Probe acquisition and the continued ramp--up of new products including tomosynthesis, PANTHER, and MyoSure systems, partially offset by an elimination of Adiana system revenues ($2.2 million in the third quarter of fiscal 2012). The company expects non--GAAP adjusted EPS of $0.36 to $0.37. The company also expects gross margins of approximately 63% and operating expenses of $190 million to $195 million or approximately 30% to 31% of revenues, up year-over-year primarily due to the inclusion of company's operating results and down sequentially from second quarter 2013 due to the timing of R&D projects, headcount reduction, cost savings initiatives and increased Gen-Probe synergies.
For the year ending September 28, 2013, the company is updating its expectation for fiscal 2013 non--GAAP adjusted revenues of $2.53 billion to $2.55 billion from its previous expectation of $2.61 billion to $2.64 billion. The updated fiscal 2013 revenue guidance represents an increase of 26% to 27% over fiscal 2012 non--GAAP adjusted revenues of $2.01 billion. This increase is expected to be driven primarily by the Gen--Probe acquisition and, to a lesser extent, revenue increases in the Breast Health, GYN Surgical and legacy Diagnostics segments, partially offset by a reduction in Adiana systemrevenues. And lastly, the company is reducing EPS guidance to a range of $1.54 to $1.56 from $1.58 to $1.60, which results to an EPS growth of 11% to 13% over last year. This reduction factors in the lower revenue guidance, coupled with reduced operating expenses from Gen-Probe synergies and other cost-saving initiatives. For gross margins, reaffirming guidance of approximately 63%.